Quantcast

Latest Interferon beta-1a Stories

2008-08-27 18:00:56

Biogen Idec today announced that enrollment is complete in the ASSURANCE trial, a long-term follow-up study which will assess up to 15 years of AVONEX(R) (interferon beta-1a) treatment in an effort to provide detailed data on the long term efficacy of the drug.

2008-07-23 03:00:22

By Blasier, Mary Gail Key Words: Multiple sclerosis, central nervous system, disease modifying therapies, quality of life. Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS), which is composed of the brain, optic nerves, and spinal cord (Graham, 2009).

2008-07-16 09:01:19

Teva Pharmaceutical Industries and Active Biotech have announced that patients are being enrolled for the Bravo Phase III pivotal trial.

2006-06-05 16:35:00

U.S. health officials cleared the way on Monday for multiple sclerosis drug Tysabri to return to the market with restrictions, following its withdrawal last year when it was linked to a rare but potentially fatal brain disease.

2006-05-31 02:13:50

LOS ANGELES (Reuters) - Teva Pharmaceutical Industries Ltd. said on Wednesday that its multiple sclerosis drug Copaxone was shown in a clinical trial to be effective in patients who had stopped responding to Avonex, a competing drug made by Biogen Idec.

2006-04-05 16:15:00

A high dose of Teva Pharmaceutical Industries Ltd.'s multiple sclerosis drug Copaxone is more effective at limiting relapses and brain lesions than the standard dose, without more side effects, researchers said on Wednesday.

2005-09-16 09:49:18

By Julie Steenhuysen and Sitaraman Shankar CHICAGO/FRANKFURT (Reuters) - A drug from Genzyme Corp. and Schering helped reduce the risk of relapses in multiple sclerosis patients, but caused a serious side effect in three cases that led to a death, the companies said on Friday.

2004-11-27 12:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc.

2004-11-26 18:00:09

FRIDAY, Nov. 26 (HealthDayNews) -- The U.S. Food and Drug Administration has approved Tysabri (natalizumab) as a new treatment for multiple sclerosis. The incurable nervous system disease affects about 350,000 Americans.

2004-11-26 06:00:07

WASHINGTON -- The government approved a drug Tuesday that tries a new method of attacking multiple sclerosis, an incurable disease of the central nervous system that affects 350,000 Americans. The drug -- a monoclonal antibody produced by Cambridge, Mass.- based Biogen Idec Inc.


Word of the Day
shavie
  • A trick or prank.
The word 'shavie' is related to 'shave'.